Top Medical News Today
Christian G. Downs, JD, MHA, discusses his thoughts on how rebuilding the 340B program should be addressed, Medicare Payment Advisory Commission’s Part B cost control proposals, and the potential for progress in tackling rising drug costs.
Brigatinib has been granted an accelerated approval by the FDA as a treatment for patients with metastatic ALK-positive non–small cell lung cancer who are resistant to prior crizotinib.
Keeping patients on their oral oncology medications involves a combination of active management, record keeping, and coordination among healthcare workers, pharmacy professionals explained during a panel discussion.
Daniel James George, MD, professor of Medicine, professor in Surgery, Duke University School of Medicine, discusses how cabozantinib (Cabometyx) is currently being used in practice for patients with renal cell carcinoma (RCC).
Midostaurin (Rydapt) has been approved by the FDA for the treatment of adult patients with newly diagnosed FLT3-positive acute myeloid leukemia (AML) in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation.
View More >
Speakers at the 2017 Community Oncology Alliance (COA) annual meeting in National Harbor, Maryland, reflect on challenges in the first year of the OCM.
Frontline Atezolizumab Approved by FDA for Treatment of Some Bladder Cancer Patients
Atezolizumab has been granted an accelerated approval by the FDA as a frontline treatment for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Enasidenib Granted FDA's Priority Review for IDH2-Mutant AML
A new drug application for enasidenib has been granted a priority review by the FDA as a treatment for patients with relapsed or refractory IDH2-mutated AML.
Alectinib Approved by EC for ALK+ NSCLC
Alectinib has been approved by the European Commission as a treatment for patients with metastatic ALK-positive non-small cell lung cancer following progression on crizotinib.
Avelumab Granted Priority Review by FDA for Metastatic Urothelial Carcinoma
A biologics license application (BLA) for avelumab has been granted a priority review by the FDA for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) whose disease has progressed after platinum-based therapy.